Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 -- Vaccinex,... | May 15, 2023

Related Keywords

Chicago ,Illinois ,United States ,Kenilworth ,Germany ,Hyos Han ,Brian Czerniecki ,Albertd Friedberg ,Maurice Zauderer ,Vaccinex Rochester ,John Mullaly ,Pfizer Inc ,Merck Kga ,Vaccinex Inc ,Co Inc ,Development Expenses ,Exchange Commission ,Merck Kgaa ,Lifesci Advisors ,Moffitt Cancer Center ,Nature Communications Paper ,Nature Communications ,Merck Sharp Dohme Corp ,University Of Rochester Cancer Center ,Wilmot Cancer Institute ,Huntington Disease Program ,Alzheimer Disease Program ,Parent Co ,Merck Co ,Nasdaq ,Platform Technology ,Chief Executive Officer ,Disease Cognitive Assessment Battery ,Nature Medicine ,Moffitt Cancer ,Recent Milestones ,Disease Program ,Annual Meeting ,American College ,Clinical Oncology ,Vaccinex Sponsored Phase ,Rochester Cancer Center ,Gateway Discovery ,Communications Paper ,Surface Oncology ,Three Months Ended March ,Cash Equivalents ,Marketable Securities ,Comprehensive Loss ,Merck Sharp ,Dohme Corp ,Sci Advisors ,Consolidated Balance Sheets ,Consolidated Statements ,Months Ended March ,Vaccinex ,Nc Stock Exchange ,News ,Information ,Press Release ,Significant ,Td ,Progress ,N ,Eurology ,End ,Ncology ,Programs ,Few ,Financing ,F ,Closed ,Without ,Derivatives ,Dr ,Mother ,Financial ,Considerations ,Bay ,023 Vcnx Us9186401033 ,